Form 4: Bicycle Therapeutics Director Receives Equity Awards

Robert Charles Swanton, a Director at Bicycle Therapeutics PLC, was granted 3,726 restricted share units and options to purchase 7,453 ordinary shares.

Summary

• Robert Charles Swanton, a Director of Bicycle Therapeutics PLC, acquired 3,726 ordinary shares through a Restricted Share Unit (RSU) award on January 2, 2026.
• Each RSU represents a contingent right to receive one ordinary share, with a transaction price of $0.
• The RSUs are scheduled to vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Following this transaction, Mr. Swanton beneficially owns 19,213 ordinary shares directly.
• Mr. Swanton also acquired options to purchase 7,453 ordinary shares on January 2, 2026, with an exercise price of $7.08 per share.
• These stock options have an expiration date of January 2, 2036.
• The options will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Following this transaction, Mr. Swanton beneficially owns 7,453 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a director, which is a neutral to slightly positive event for retention and alignment of interests.

Positives

• The equity awards align the director's interests with those of shareholders, promoting long-term commitment and performance.
• The grants represent a form of compensation and incentive for the director's continued service to Bicycle Therapeutics PLC.

Future Outlook

The future outlook involves the vesting of the granted restricted share units and stock options in four equal installments throughout 2026, leading to an increase in the director's direct beneficial ownership of ordinary shares and exercisable options.

Industry Context

This filing is a standard disclosure of insider equity compensation, common across all industries, particularly in biotechnology where long-term incentives are crucial for retaining key talent and aligning interests with company growth.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon vesting and exercise of awards, but also improved alignment of interests between the director and the company's long-term performance.
• Director: Increased equity stake and long-term incentive, enhancing personal wealth tied to company success.

Next Steps

• Vesting of 3,726 Restricted Share Units in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Vesting of options to purchase 7,453 ordinary shares in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Potential exercise of vested stock options by the director before the expiration date of January 2, 2036.

Key Dates

Keywords

Bicycle Therapeutics, BCYC, Form 4, insider transaction, equity award, restricted share unit, RSU, stock option, director compensation